Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
about
Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.Analysis of medical use of carbon adsorbents in China and additional possibilities in this field achieved in Ukraine.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system.
P2860
Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Granulocyte-colony stimulating ...... ith early-stage breast cancer.
@en
Granulocyte-colony stimulating ...... ith early-stage breast cancer.
@nl
type
label
Granulocyte-colony stimulating ...... ith early-stage breast cancer.
@en
Granulocyte-colony stimulating ...... ith early-stage breast cancer.
@nl
prefLabel
Granulocyte-colony stimulating ...... ith early-stage breast cancer.
@en
Granulocyte-colony stimulating ...... ith early-stage breast cancer.
@nl
P2093
P2860
P1433
P1476
Granulocyte-colony stimulating ...... with early-stage breast cancer
@en
P2093
Gary H Lyman
Jason C Legg
Mark D Danese
Michelle L Gleeson
Richard L Barron
Robert I Griffiths
Victoria M Chia
P2860
P304
P356
10.2165/11589440-000000000-00000
P577
2012-02-01T00:00:00Z
P6179
1025712472